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Background: The matching of favorable human leukocyte antigen (HLA) combinations is rarely performed in penetrating keratoplasty procedures for primary prophylaxis of immune
reactions. However, clinical studies suggest that the incidence of graft rejection decreases substantially when patients receive favorably matched grafts.
Objective: The aim of this study was to assess the cost-effectiveness of HLA matching for patients undergoing penetrating keratoplasty in everyday clinical practice.
Methods: In the absence of a randomized controlled clinical trial, we used administrative data from the Freiburg University Eye Hospital in Germany. Our study population consisted
of all patients who underwent their first keratoplasty between 11/2003 and 01/2010 and for whom information on HLA histocompatibility was available. We used propensity
score matching to estimate a causal effect of favorable HLA matching, parametric survival regression techniques to predict graft survival and expert opinion to model incremental cost
for HLA matching. Because the availability of favorable HLA histocompatibility ultimately depends on the patients’ HLA phenotype, we modeled the incremental cost-effectiveness
ratio (ICER) as a function of the probability that a patient will receive a favorably matched HLA, and used expert opinion to set a point estimate.
Results: We predicted that corneal grafts with favorable HLA matching were associated with improved rejection-free graft survival time (more than 1,000 days). We estimated the
incremental cost of HLA matching at EUR 1,200 and the ICER at EUR 4.62 per additional day of graft survival.
Conclusions: The ICER of HLA matching is acceptable, given the high cost of alternative treatment and the shortage of corneal donors in Germany.
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The economic and social burden of blindness is immense. In
Germany alone, the direct cost associated with visual distur-
bances and blindness (ICD-10 H53–54) was €359 million in
2008, up from €280 million in 2002 (1). Apart from its eco-
nomic cost, blindness also leads to a dramatic decrease in quality
of life (2). Severe corneal disease, one of the major causes of
blindness, can be treated with a procedure known as penetrating
keratoplasty, which entails removing a patient’s diseased cornea
and replacing it with donated corneal tissue (3).
Based on data from the Australian Corneal Graft Registry,
Coster and Williams (4) found that despite the use of topical
steroids, the cumulative survival rate for corneal grafts 5 years
after implantation was less than 70 percent. This graft rejection
leads to a substantial worsening of vision. Systemic immuno-
prophylaxis can be used to decrease rejection rates, but the side
effects of immunosuppressants may both outweigh the benefits
associated with longer graft survival (5) and cause high cost for
the healthcare system, with a daily defined dose (DDD) costing
nearly EUR 13. Re-interventions after rejection represent a fur-
ther drain on resources, as some patients must undergo repeat
keratoplasties at high cost. Finally, supply of grafts is limited
because it is based on the availability of donor tissue. Germany’s
shortage of corneal grafts is apparent in the number of patients
on the transplant waiting list: as of 31 December 2008, 2,281
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patients were awaiting corneal transplant (data made available
upon request from the German Keratoplasty Registry, which is
managed by the University of Saarland on behalf of the Cornea
Section of the German Ophthalmological Society). Although
artificial corneas, known as keratoprostheses, may present an
alternative to grafts at some point in the future, their use to date
has been limited to a small group of patients (6). Therefore,
cost-effective measures to reduce the number of graft rejections
from penetrating keratoplasty remain sorely needed.
Several studies have shown that favorable matching for hu-
man leukocyte antigens (HLA) between donors and recipients
has a positive impact on rejection-free graft survival. HLA
Matchmaker is a novel “in silico” approach to HLA match-
ing developed by Duquesnoy (7), which uses a comprehensive
database to predict the set of antibody-accessible epitopes from
any HLA phenotype. This method allows a more sophisticated
approach to matching than conventional uniform “stacking” of
all foreign alleles: multiple HLA-mismatches commonly share
antibody epitopes and thus do not count fully as suggested by
conventional matching. The observation that certain “taboo”
mismatches are more immunogeneic than others (8) supports
this concept. The HLA Matchmaker technique has been devel-
oped and successfully applied to penetrating keratoplasty by
Böhringer et al. (9), and the technique has been associated with
a substantial prolongation of rejection-free graft survival (a de-
tailed description of the procedure is presented in Böhringer
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et al.) (9). Based on an exploratory and a confirmational co-
hort, the authors classified the histocompatibility patterns into
three groups: (a) favorable match: fewer than 10 mismatched
HLA-class I eplets combined with a beneficial HLA-class I and
class II matching balance; (b) neutral match: fewer than 10 mis-
matched HLA-class I eplets or an unfavorable HLA-class I and
class II matching balance; (c) unfavorable match: more than 10
mismatched HLA-class I eplets and an unfavorable HLA-class
I and class II matching balance.
This classification was highly predictive of immune reac-
tions in both exploratory and confirmational datasets and seems
to be very promising.
Although implanting favorably matched grafts seems to of-
fer an advantage over assigning grafts without regard to HLA
phenotype, the European Eyebank Association (EEBA) surveys
suggest that the percentage of HLA-matched transplantations
in Europe may be as low as 2 percent. Economic factors might
be responsible for this low rate. As soon as any hospital de-
cides to offer HLA matching, all patients and available grafts
must be HLA-typed. However, not all patients who undergo
HLA matching will actually receive favorably matched grafts
within a reasonable timeframe. The availability of histocom-
patible grafts ultimately depends on the population frequencies
of the individual HLA phenotypes. Even if HLA matching is
part of routine care, rare phenotypes are not likely to receive
a matched graft due to a prohibitively small pool of HLA-
typed compatible donors (10). Thus, only the share of patients
who receive a favorably matched graft will benefit from HLA
matching. Moreover, HLA matching offers no additional bene-
fit to those patients who might in any case receive a favorably
matched graft just by chance. Thus, although HLA matching
does incur an incremental cost, there is enormous uncertainty
about the incremental effectiveness of providing HLA matching
in everyday clinical practice. For this reason, an economic eval-
uation of HLA matching is inherently different from evaluation
of other technologies.
To provide a framework for evidence-based decisions re-
garding the provision of HLA matching in routine care for all
patients, decision makers therefore need information about (a)
the incremental cost of HLA matching and (b) the incremen-
tal effects of HLA matching on graft survival. The latter is
closely related to the proportion of patients who will—after
HLA matching—be able to receive a favorably matched graft
they would not have received by chance.
Although the matching approach of Böhringer et al. (9)
seems to have a significant effect on graft survival, no economic
study to date has evaluated this procedure. We aim to fill this gap
with the present analysis. First, we aim to give an estimate for the
incremental cost of HLA matching in penetrating keratoplasties.
Second, we intend to measure the incremental effect of favor-
ably matched grafts in terms of rejection-free graft survival. As
the matching technique by Böhringer et al. has only been devel-
oped recently, data from a randomized controlled clinical trial
(RCT) that compares patients who have undergone HLA match-
ing with patients who have not undergone HLA matching are not
yet available. To estimate a causal effect in a non-RCT setting,
we use a state-of-the-art propensity score matching approach.
To deal with right-censored data, we use parametric regression
techniques to extrapolate median survival times. Based on the
incremental effect of favorable matches on rejection-free graft
survival, we suggest an approach which accounts for the uncer-
tainty regarding the availability of favorably matched grafts and
give an estimate for an ICER based on expert opinion.
This study is structured as follows: In the Methods section,
we present the methods we used to address these research
questions; in the Results section, we discuss our results; and




In the absence of data from a randomized controlled trial or
prospective data, we used retrospective clinical data derived
from all patients who underwent a penetrating keratoplasty at
the Freiburg University Eye Hospital between 1 November 2003
and 31 January 2010. During this period, a total of 1,495 pene-
trating keratoplasties were performed. For the purposes of scien-
tific research, the hospital routinely typed the HLA of all patients
and most of the grafts, even when an HLA-matching graft was
not actively sought. However, prospective conventional HLA
matching was only performed on a subset of patients who were
classified as “high-risk,” as described below. We excluded all pa-
tients for whom we did not have information on the patient’s and
grafts’ HLA. We also excluded all patients who had undergone
repeat keratoplasties because including them in our analysis
would have complicated the propensity score matching pro-
cedure. HLA histocompatibility was classified retrospectively
based on HLA information from patient and donor. The novel
classification scheme developed by Böhringer et al. (9) was
used and we distinguished between three types of HLA histo-
compatability based on HLAMatchmaker eplets: (a) favorable,
(b) neutral, and (c) unfavorable. Both neutral and unfavorable
matches were defined as a reference to assess the incremental
benefit of favorable matching on rejection-free graft survival.
All patients consented to scientific analysis of the routine data,
and permission was obtained from the ethics committee of the
Freiburg University Hospital.
All data were obtained by reviewing patient charts, which
included information on the age and gender of each patient, as
well as their indication for penetrating keratoplasty. Unfortu-
nately, cost data was not available in the patient records. In the
present study, we distinguished between indications with (i) a
high or (ii) a low number of patients. The first group consisted of
patients with keratoconus, Fuchs’ endothelial dystrophy, avas-
cular corneal scars, or degeneration of the corneal endothelium
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(bullous keratopathy). The second group consisted of patients
with any other indication. Graft rejections were defined as en-
dothelial precipitates, newly diagnosed corneal edema (not at-
tributable to increased intraocular pressure), nummular stromal
infiltrates in the graft or epithelial rejection lines. The hospital
also classified implants as low-risk or high-risk, according to
their estimated risk of rejection based on whether the proce-
dures involved repeat keratoplasties, vascularized corneas, or
surface disorders, etc. (11;12). Graft failures that did not result
from graft rejections were not used as endpoints. We created
a variable which assumed a value of one if a graft rejection
occurred during the study period, or a value of zero if no graft
rejection occurred during the study period. Event-free time (i.e.,
time without rejection) was calculated in days and defined as
the time until the graft was rejected or the patient was seen
for the last time. In the latter case, the true survival time of
the corneal graft was unknown and the data were considered
right-censored.
Propensity Score Matching
Because we analyzed the administrative data retrospectively, we
could not rule out that patients in the favorable matches group
differed substantially in terms of characteristics that are asso-
ciated with the survival time of the graft. To preclude the pos-
sibility that increased rejection-free graft survival time was not
chiefly attributable to patient characteristics, we used propen-
sity score matching to compare only patients with favorable
matches and controls who were homogeneous in terms of their
outcome-relevant characteristics (13). There are several eco-
nomic evaluations based on secondary data that take similar
approaches, for example, Bäumler et al. (14). The propensity
score Pi (i.e., the probability of keratoplasty i being assigned
to the favorable match cohort) aimed to control for all char-
acteristics which are known to be associated with graft re-
jections. This was defined as a function of patient age, pa-
tient gender, the risk of graft rejection, and the indication for
keratoplasty, as follows: Pi (X) = F (age, gender, risk status,
indication).
To estimate the propensity score, we used a logistic re-
gression. We subsequently attempted to match patients in the
favorable match cohort with controls who had roughly the same
propensity scores. There are several methods for matching (for
an overview see Austin (15;16)). As our principal aim was to
reduce heterogeneity between the two groups, we opted for
the one-to-one nearest neighbor matching method with replace-
ment and a calipers of width equal to 0.01. The same control
could theoretically be used for several patients in the favorable
match cohort. If no suitable control for a patient in the favor-
able match cohort was found within a caliper of 0.01 around his
or her propensity score, this patient was excluded from further
analysis to minimize differences between the groups. The width
of 0.01 was chosen as it resulted in a good trade-off between
heterogeneity and sample size. Standardized Differences (SDF)
for each outcome-relevant variable were used to evaluate the
goodness-of-fit. SDFs below a threshold of 10 percent suggest
that favorable match cohort and control cohort differed only
in the HLA-matching classification of the graft (i.e., favorable
versus neutral or unfavorable) (16).
Incremental Cost
In the absence of cost data in the patient records, we modeled
cost based on treatment guidelines published by the German
Society of Ophthalmologists (7) and expert opinions provided
by ophthalmologists of the Freiburg University Eye Hospital.
Because our analysis was conducted from the perspective of
the payer, we did not consider indirect cost (8). According to
these sources, total cost for patients who undergo a penetrating
keratoplasty comprise (a) the cost of the graft itself, (b) the cost
of hospital admission and the keratoplasty procedure, and (c)
the cost of follow-up visits and medication during the follow-up
period. The treatment guidelines state that resource consump-
tion during the follow-up period is the same regardless of HLA
matching. This also holds for the keratoplasty procedure and
hospital admission. Thus, the only incremental cost incurred
is in the preparation of the graft. According to expert opinion,
the only difference between grafts prepared for HLA matching
and randomly selected grafts is that HLA matching involves
typing of both patient and donor (i.e., two times the cost for one
typing procedure). The cost of matching software is virtually
negligible.
Incremental Effect of Favorable Matches on Rejection-Free Graft Survival
As the patient charts do not provide information on patient-
related outcomes such as utility values, we chose graft sur-
vival as an outcome measure, defined as rejection-free graft
survival time. First, we used Kaplan-Meier estimates to illus-
trate rejection-free graft survival time. For the vast majority
of datasets included in our analysis, the true survival time of
corneal grafts was unknown because rejection did not occur dur-
ing the study period. Our data was thus heavily right-censored.
We therefore relied on a regression-based extrapolation of me-
dian rejection-free graft survival time (20), defining the survival
time Si of graft i as a function of patient age, gender, risk of
graft rejection, indication, and HLA matching classification:
Si = F (age, gender, risk status, indication, HLA matching
classification).
As a distribution for the survival regression, we used the
Weibull distribution which seemed to be suitable for our pur-
poses, as it allows flexibility. Because the decision regarding
which distributions to use for the regression model is ultimately
arbitrary, (19) different distributions were considered in the sen-
sitivity analyses. Subsequently, we used the estimates from the
hazard regression to predict the median rejection-free graft sur-
vival time for an average patient with and without favorable
HLA matching.
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Figure 1. Illustration of treatment options.
Incremental Cost-Effectiveness-Ratio
To provide information about the cost-effectiveness of this pro-
cedure, we aimed to calculate an incremental cost-effectiveness
ratio (ICER). An ICER is defined as
ICER = Cost
Eff ectiveness
The raw ICERR below represents the formula which would
have been used had we been able to ascertain that all patients
who had undergone HLA matching had received a favorably
matched graft and, in addition, had not been able to receive a
favorably matched graft without HLA matching:
ICERR = Cost
Survival
where Cost is the cost for HLA typing and Survival is the in-
cremental rejection-free graft survival of the favorably matched
graft. However, in a real-world setting there is uncertainty about
the effectiveness of HLA matching because, due to the limited
availability of various HLA phenotypes in grafts, only a share
of patients will be able to receive a favorably matched graft after
HLA matching. In addition, even if the hospital does not use
HLA matching and no cost are incurred from HLA typing, a
certain proportion of patients will receive a favorably matched
graft merely by chance.
To account for this in our economic analysis, we made
the following adjustments to the raw ICER. The share of pa-
tients receiving a favorably matched graft is represented as π
(0 ≤ π ≤ 1) and the effectiveness of HLA matching is repre-
sented as π times the incremental gain in graft survival time,
where π depends on the availability of HLA phenotypes with a
favorable histocompatibility. The share of patients who will re-
ceive a favorably matched graft merely by chance is represented
by τ (0 ≤ τ ≤ 1). The effectiveness of not conducting HLA
matching thus equals τ times the incremental gain in graft sur-
vival time, where τ is a stochastical function of the availability
of matching grafts, which is referred to in the parameter π . π is
thus by definition greater than or equal to the share τ . Figure 1
illustrates these uncertainties in a decision-tree structure.
Following this, the share of patients that does benefit from
HLA matching by receiving a favorably matched graft is defined
as (π − τ ). A corrected ICER which accounts for uncertainty
regarding the availability of grafts with a favorable HLA histo-
compatibility is thus defined as
ICERC = Cost
(π − τ )Survival =
1
(π − τ ) ICERR
The corrected ICER is therefore a function of the inverse share
of patients who receive a favorably matched graft due to HLA
matching. In the absence of data that would enable the authors
to estimate the parameters π and τ , we draw on expert opinion
from ophthalmologists to give a point estimate for the ICER.
Sensitivity Analyses
Apart from uncertainty regarding the proportion of patients
(π – τ ) that benefit from HLA matching, further uncertainty
was present in our results regarding (i) our extrapolation tech-
nique and (ii) the cost of the intervention. Therefore, we also
performed multivariate sensitivity analyses to test our results’
robustness. To account for uncertainty regarding our choice of
a Weibull distribution, we extrapolated the incremental survival
time using exponential, log-logistic, and log-normal distribu-
tions. Given that HLA typing is a mostly automated procedure,
we reckoned it was reasonable to assume economies of scale
when the number of typed grafts increased. Estimating a lower
cost for one typing procedure might therefore more accurately
reflect the future cost of such procedures.
RESULTS
Baseline Characteristics of the Patients
In our data set of 721 keratoplasties, we identified 118 patients
in the favorable match cohort and 603 in the control cohort. The
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Table 1. Characteristics of the Study Population











Variable Mean / % Mean / % p-Value
SDF before
PSM Mean / % Mean / %
SDF after
PSM  SDF
Age 58.7 (19.7) 52.9 (18.9) .003 29.9% 53.2 (17.5) 53.3 (18.7) 0.8% −29.2%
Female patients 47.8% 36.4% .024 47.0% 37.4% 37.4% 0.0% −47.0%
High-risk patients 23.9% 38.1% .001 67.7% 37.4% 39.1% 7.4% −60.3%
Common indications 85.9% 79.7% .083 43.6% 80.0% 79.1% 5.3% −38.3%
Standard deviation in parentheses for continuous variables.
The p values are derived from T-test (continuous variables) and chi-square tests (categorical variables).
SDF= standardized difference.
SDF for most of the variables was rather high. Detailed descrip-
tions of patient baseline characteristics are given in Table 1.
Propensity Score Matching
To ensure that our propensity score matching would minimize
all potential biases, we included a large number of variables
and made certain that diverse interactions between the vari-
ables were considered in the logistic regression (the results of
the regression are available upon request from the authors).
Propensity score matching led to a substantial reduction in het-
erogeneity (see Table 1), with the SDF for all variables remain-
ing below a threshold of 10 percent. The total sample size was
reduced to 230 (with 115 patients in each cohort) because we
were unable to find comparable controls for three of the original
118 patients in the favorable match cohort.
Cost Analysis
We assumed a cost of EUR 600 for each typing procedure
based on Böhringer et al. (20). As there are virtually no cost
differences between matched and randomly selected grafts, and
incremental cost is the sum of the cost for typing the graft and
the patient, the total incremental cost was estimated at EUR
1,200.
Rejection-Free Graft Survival Time Prediction
Figure 2 shows the Kaplan-Meier survival curves. The favorable
match cohort is shown in blue and the control cohort in red. Data
for a substantial share of patients were right-censored. There
were a total of 20 corneal graft rejections in the favorable match
cohort and 28 in the control group during the study period.
After 776 days, no known graft rejections took place in the
favorable match cohort, whereas in the control cohort several
graft rejections did occur.
Results from the regression model suggest that favorable
HLA matching based on HLA Matchmaker-defined eplets was
significantly associated with rejection-free graft survival time
(P = 0.04). We estimated a survival time of 2,573 days in the
favorable match group and 1,444 days in the control group. The
incremental effect of receiving a favorable match on rejection-
free graft survival is thus 1,129 days.
Incremental Cost-Effectiveness Ratio and Sensitivity Analyses
We calculated a raw ICERR of EUR 1.06 for each additional
day of graft survival. This raw value represents what the ICER
would have been had all patients received a favorably matched
graft and the probability of receiving such a graft without HLA
matching were zero. The corrected ICERC was thus defined as
ICERC = 1π−τ 1.06.
For the parameters π and τ , we used estimates that were
agreed upon by experts in ophthalmology from the Freiburg
University Hospital who have longstanding experience in con-
ducting penetrating keratoplasty and HLA matching. We as-
sumed that the share of patients who received a favorably
matched graft by chance (our parameter τ ) was lower than
10 percent. Experts believe that if patients undergo prospective
HLA matching more than one third of the patients will receive
a favorably matched graft. For our analysis, therefore, conser-
vative estimates for the parameters τ and π (τ = 0.1 and π =
0.33) were assumed. Based on these figures, the share of the pa-
tients receiving a favorably matched graft due to HLA matching
equaled 0.23, yielding a point estimate of EUR 4.62 for each
additional day of graft survival. This result and the distribution
of ICERC is shown in Figure 3.
Point estimates for the sensitivity analyses range from EUR
2.10 to EUR 6.71 per additional day of graft survival. Table 2
sums up the results of the sensitivity analyses.
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Figure 2. Kaplan-Meier survival curves.
Figure 3. Raw ICER as a function of (π – τ ). The point estimate for the ICER is marked with X.
DISCUSSION
We conducted a retrospective cohort study of patients who had
undergone penetrating keratoplasty at the Freiburg University
Eye Hospital to assess the incremental cost and effectiveness
of favorable HLA matching using HLA Matchmaker-defined
eplets. Cost was modeled based on treatment guidelines from
a payer’s perspective. Effectiveness was defined as rejection-
free survival time of the corneal graft. To our knowledge, our
study is the first to investigate the cost and effectiveness of HLA
matching in penetrating keratoplasty.
HLA matching is associated with higher cost because both
patient and graft must be HLA typed. We assumed an incre-
mental cost of EUR 1,200 for HLA matching (twice the cost
of EUR 600 for each typing). However, given that HLA typ-
ing is a mostly automated procedure, we consider it reasonable
to assume that the typing cost would decrease when further
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Table 2 Results Including Sensitivity Analyses
Distribution
Weibull
(Baseline analysis) Exponential Log-log Log-normal
Incremental cost € 1,200 € 600 € 1,200 € 600 € 1,200 € 600 € 1,200 € 600
Incremental survival 1,129∗∗ 1,129∗∗ 1,244∗∗ 1,244∗∗ 970∗ 970∗ 777 777
Raw ICER € 1.06 € 0.53 € 0.96 € 0.48 € 1.24 € 0.62 € 1.54 € 0.77
per day per day per day per day per day per day per day per day
ICER estimate € 4.62 € 2.31 € 4.19 € 2.10 € 5.38 € 2.69 € 6.71 € 3.36
per day per day per day per day per day per day per day per day
This raw ICER has to be multiplied with the inverse share of patients who receive a favorably matched due to HLA matching.
∗p< 0.1
∗∗p< 00.05
hospitals implemented HLA matching, based on the principle
of economies of scale. We found favorable HLA matching had
a significant effect on rejection-free graft survival time. Results
were robust to various distributions of the hazard function; only
in the log-normal model did favorable matches not have a signif-
icant impact on graft survival. We therefore conclude that favor-
able HLA matching based on HLA Matchmaker-defined eplets
is significantly associated with longer rejection-free graft sur-
vival time. Böhringer et al. (9), who devised the HLA-matching
technique upon which our analysis is based, obtained results
comparable to ours, albeit without having performed propen-
sity score matching. We found a raw ICER of EUR 1.06 per
additional day of graft survival, which was multiplied by the
inverse of the share of patients that benefited from HLA match-
ing. Based on a very conservative expert opinion, we estimated
an ICER of 4.62 per additional day of graft survival. Results
of the sensitivity analyses ranged from EUR 2.10 to EUR 6.71.
Our findings were most sensitive to incremental cost, whereas
they are less sensitive to the assumption of various distributions.
If all eye banks typed grafts routinely, it would be reasonable
to assume that the share of patients that received a favorably
matched graft would increase substantially. As a consequence
of this, the ICER would decrease.
Our analysis was based on patient claim data. We thus did
not have information on patient-reported outcomes. In addition,
there are no utility values for patients who underwent a pene-
trating keratoplasty in the literature. As a result, we could not
estimate a cost per quality-adjusted life-year (QALY) ratio and
had to rely on surrogate outcomes such as the chosen rejection-
free graft survival that was available in our dataset. In contrast
to a cost per QALY ratio, there is no accepted threshold for cost
per additional day of graft survival. Subsequently, we cannot
judge the absolute superiority of this technique. However, by
comparing the cost of alternative treatment strategies, we can
evaluate its relative superiority.
An alternative strategy for decreasing the rejection rates of
corneal grafts is the intake of cyclosporin A or mycophenolate
mofetil (21;5). However, not only do such treatments cause side-
effects harmful to the patient, but cost from a payers’ perspective
are higher. According to the German pharmaceutical catalogue
Rote Liste, both treatments incur a cost of nearly EUR 13 per
day. This is substantially higher than our estimated ICER of
EUR 4.62 for HLA Matching. Based on our raw ICER, HLA
matching is superior if at least 9 percent of the patients receive
a favorably matched graft due to HLA matching (where the
patient share is π - τ ).
However, even if the share of patients is lower than this per-
centage, there is a high probability that this technology is cost-
effective. When conducting an economic evaluation of trans-
plantation techniques, it is important to consider that grafts are
inherently different from other medical technologies. The de-
mand for grafts significantly surpasses the number of available
donors, creating a shortage of grafts worldwide. However, the
high shadow value of grafts resulting from this scarcity cannot
be factored into the pricing of grafts in economic evaluations be-
cause assigning monetary value to human body parts is widely
viewed as unethical. This suggests that we tend to underestimate
the value of transplantation techniques that increase (a) the sur-
vival time of grafts and thus (b) the number of available grafts
within the regulated systems for allocating these grafts. Given
that the estimated ICER in our study did not take into account
the nonmonetary value of grafts, it is reasonable to assume that
favorable HLA matching is cost-effective.
Limitations
This study has several important limitations. First, our analysis
is not based on RCT data but on a retrospective observational
study. We used a propensity score matching technique to account
for all known characteristics that might be associated with the
survival time of the graft, and we included various interactions
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between the variables. Although this led to a balance in both
cohorts in terms of observable characteristics, we cannot en-
tirely rule out the presence of unobservable characteristics that
might have confounded our results. Second, it is important to
keep in mind that we had to extrapolate the rejection-free graft
survival time far beyond the last available data point. Several
economic evaluations have calculated restricted mean survival
time to tackle the problem of censored data and the resulting de-
crease in the reliability of Kaplan-Meier estimates (22;23). If we
had chosen this method, however, our study period would have
comprised only 776 days. Considering the average rejection-
free survival times of corneal grafts reported in other studies
(e.g., Böhringer et al.) (9), this period would have been too short
to evaluate the effects of HLA matching on rejection-free graft
survival time. This applies in particular to grafts that do not
fail immediately after an endothelial immune reaction. In such
cases, the graft clears but suffers a substantial loss of nonregen-
erative endothelial cells, generally shortening its lifespan (24).
In addition, the true distribution of the hazard shape was un-
known. We addressed this uncertainty by allowing for various
distributions in the sensitivity analyses.
Third, in the absence of evidence regarding the share of
patients that receive a favorably matched graft following HLA
matching in a real-world setting, we had to draw on expert opin-
ion to estimate an ICER. To give a conservative estimate for the
effectiveness of HLA matching, the parameters we used for
the analysis tended to (a) overestimate the share of patients that
receive a favorably matching graft in the absence of HLA match-
ing just by chance and (b) underestimate the share of patients
that receives a favorably matched graft after HLA matching.
CONCLUSIONS
Favorable HLA matching based on a HLA Matchmaker ap-
peared to be associated in everyday clinical practice not only
with significantly longer rejection-free graft survival times but
also with additional cost. Taking into account the peculiarities of
grafts, our results suggest that the implementation of favorable
HLA matching could in fact be viewed as cost-effective.
Given the innovative nature of the technology in question,
however, we consider these results to be initial and recognize
that further research is needed to evaluate the economic impact
of the procedure. Future studies would preferably incorporate
RCT data, and more comprehensive information regarding the
share of patients receiving a favorably matched graft after HLA
matching.
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11. Böhringer D, Reinhard T, Sundmacher R. Systematische EDV-gestützte
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